Scinai Immunotherapeutics Ltd.
SCNI evidence brief
What we can confirm
- Market Cap:
- $1.7M
What it means
What to watch
Prepared research question
What matters most for SCNI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCNI
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with a dual business model combining in-house R&D in inflammation and immunology (including NanoAbs and the PC111 program) with a contract development and manufacturing (CDMO) platform, aiming to manage development risk and capital constraints [sec · filed 2026-04-01].
Key risk: No commercialized products
Market Cap
$1.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with a dual business model combining in-house R&D in inflammation and immunology (including NanoAbs and the PC111 program) with a contract development and manufacturing (CDMO) platform, aiming to manage development risk and capital constraints [sec · filed 2026-04-01].
- Dual business model: Scinai operates both a drug development unit (Scinai R&D) and a CDMO platform (Scinai Biopharma Services Ltd.) to generate revenue and support pipeline development [sec · filed 2026-04-01].
- Cash & equivalents of $1.7M and shareholders' equity of $8.1M as of 2025-12-31 [sec].
- Pipeline includes NanoAbs (VHH antibody fragments) from MPG/UMG collaboration targeting clinically validated pathways, and the PC111 program (fully human monoclonal antibody) with EMA orphan drug designation for pemphigus [sec · filed 2026-04-01].
- CDMO platform supports recombinant proteins, antibodies, peptides, small molecules, and oligonucleotides, with integration into Recipharm's network for lifecycle support [sec · filed 2026-04-01].
- The company has not yet commercialized any product candidate and may never become profitable [sec · filed 2026-04-01].
What works
- Dual business model combining R&D and CDMO operations provides operational expertise in CMC, generates external revenues, and supports internal pipeline development [sec · filed 2026-04-01].
- Access to externally sourced assets with defined biological rationale and potential regulatory advantages, such as PC111 with EMA orphan drug designation, may offer expedited regulatory pathways [sec · filed 2026-04-01].
- Focus on clinically validated targets for NanoAb programs may reduce scientific risk and support more efficient development [sec · filed 2026-04-01].
- Integration with Recipharm allows client programs to transition from early-stage to commercial manufacturing, enabling participation in downstream economics [sec · filed 2026-04-01].
What to weigh
- The company has not yet commercialized any product candidate and may never become profitable [sec · filed 2026-04-01].
- The IL-17 program is under strategic review; there is no assurance that the program will continue under its current structure, timeline, or at all, which could result in loss of rights under the license agreement [sec · filed 2026-04-01].
- Cash & equivalents of $1.7M as of 2025-12-31 is relatively low for a biotech with multiple R&D programs and no commercial revenue [sec].
- The company's CDMO business faces uncertainty in scaling commercial activity and client acquisition, with no assurance of sustained growth [sec · filed 2026-04-01].
From the filings
Quoted directly from source documents.
Dual business model combining R&D and CDMO operations
“We are a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of innovative therapeutics in inflammation and immunology, and (ii) our contract development and manufacturing organization (CDMO) business, which operates through”
SEC filings · April 1, 2026
PC111 has orphan drug designation from EMA for pemphigus
“PC111, which has received orphan drug designation for pemphigus from the European Medicines Agency”
SEC filings · April 1, 2026
No product candidate has been commercialized
“We have not yet commercialized any product candidate(s), and we may never become profitable.”
SEC filings · April 1, 2026
Risks & what to watch (4)›
Key risks
- No commercialized products — The company has not yet commercialized any product candidate and may never become profitable [sec · filed 2026-04-01].
- IL-17 program uncertainty — The IL-17 program is under strategic review; discontinuation could result in loss of license rights and materially affect business [sec · filed 2026-04-01].
- Low cash reserves — Cash & equivalents of $1.7M as of 2025-12-31 is limited for a biotech with multiple R&D programs and no commercial revenue [sec].
- CDMO growth uncertainty — No assurance of sustained growth in CDMO business through client acquisition or repeat engagements [sec · filed 2026-04-01].
What to watch
- Strategic decision on the IL-17 program: any modification, delay, or discontinuation could affect license rights and business prospects [sec · filed 2026-04-01].
- Progress of the PC111 program, including potential clinical milestones and regulatory interactions given its orphan drug designation [sec · filed 2026-04-01].
- CDMO business development: ability to scale commercial activity and acquire new clients [sec · filed 2026-04-01].
- Cash runway and potential need for additional financing given $1.7M cash as of 2025-12-31 [sec].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run Scinai Immunotherapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scinai Immunotherapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$15K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 24,041 | $13K |
| rhumbline advisers | 1,878 | $1K |
| ubs group ag | 919 | $524 |
| morgan stanley | 58 | $33 |
Short Interest
as of May 1, 2026- % of float
- 2.1%
- Days to cover
- 1.4
- Shares short
- 72,973
- Daily short volume (Aug 13, 2026)
- 50.7%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCNI short interestFrequently asked questions
What is the AI investment thesis for Scinai Immunotherapeutics Ltd.?
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with a dual business model combining in-house R&D in inflammation and immunology (including NanoAbs and the PC111 program) with a contract development and manufacturing (CDMO) platform, aiming to manage development risk and capital constraints [sec · filed 2026-04-01].
Who is the CEO of Scinai Immunotherapeutics Ltd.?
Mr. Amir Reichman M.B.A., M.Sc. is the chief executive officer of Scinai Immunotherapeutics Ltd. (SCNI).
Where is Scinai Immunotherapeutics Ltd. headquartered?
Scinai Immunotherapeutics Ltd. (SCNI) is headquartered in Jerusalem, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.